RBC Capital Markets adjusted their outlook on Morgan Stanley (NYSE:MS) shares, raising the price target from $122.00 to $142.00. The firm maintained a Sector Perform rating on the stock. The upgrade comes as Morgan Stanley's stock trades near its 52-week high of $136.
In a report released on January 21, Richard Chamberlain from RBC Capital maintained a Buy rating on Next plc (NXT – Research Report), with a
RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of
Morgan Stanley's profit more than doubled in the fourth quarter, fueled by a wave of dealmaking and stock sales that drove its revenue to a full-year record.
RBC Capital Markets analyst Maurice Choy identifies relative “safer havens” in the yield-heavy energy infrastructure sector, National Bank economist Warren Lovely noted the important fact that global interest in Canadian bonds remains high,
“We think Morgan Stanley benefits from favorable secular trends in the capital markets, wealth management, and investment banking,” he said in a research note. Morgan Stanley’s revenue from ...
Daniel Fannon; Analyst; Jefferies & Company Inc. Gerard Cassidy; Analyst; RBC Capital Markets
Morgan Stanley, a juggernaut in the wealth management industry, has been repeatedly ahead of its peers when it comes to crypto.
The round, which values Databricks at $US62 billion, was led by Temasek, Macquarie Capital and Qatar’s sovereign wealth fund QIA. Meta also joined as a strategic investor.
Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $14.55 which represents a slight increase of $0.42 or 2.97% from the prior close of $14.13. The stock opened at $14.3 and touched a low of $13.
In a report released today, Bob Huang from Morgan Stanley maintained a Hold rating on W. R. Berkley Corporation (WRB – Research Report), with a
In a report released today, Nik Modi from RBC Capital maintained a Buy rating on Monster Beverage (MNST – Research Report), with a price target